Corcept Therapeutics (CORT) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Corcept Therapeutics (CORT) over the past year, gaining 125.8% versus a loss of 17.7%. Over five years, KNSA leads with a +706.0% price change compared with +196.0% for CORT. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $6.96 billion), about 1.1 times the size.
On valuation, Corcept Therapeutics trades at a lower forward P/E (12.8x vs 45.9x for Kiniksa Pharmaceuticals International). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus 8.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | KNSA |
|---|---|---|
| Share price | $63.62 | $93.90 |
| Market cap | $6.96B | $7.38B |
| 1-day change | -2.09% | +0.38% |
| YTD return | +82.82% | +127.62% |
| 1-year return | -17.69% | +125.82% |
| 5-year return | +196.04% | +705.97% |
| P/E ratio (TTM) | 47.83 | 71.13 |
| Forward P/E | 12.77 | 45.91 |
| EPS (TTM) | $1.33 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $677.56M |
| Revenue growth (YoY) | +12.79% | +60.09% |
| Net income (latest FY) | $99.65M | $59.01M |
| Gross margin | 98.30% | 88.54% |
| Operating margin | 5.88% | 11.40% |
| Net margin | 13.09% | 8.71% |
| 52-week high | $126.38 | $99.31 |
| 52-week low | $28.66 | $37.02 |
| Distance from 52-week high | -49.66% | -5.45% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +124.14% | +18.82% |
| Average volume | 1.26M | 664.53K |
| Shares outstanding | 109.44M | 48.84M |
| Employees | 730 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed CORT by 143.5 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (71.1x vs 47.8x trailing P/E).
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +12.79%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
CORT vs KNSA FAQ
Which is bigger, Corcept Therapeutics or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $6.96B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, CORT or KNSA?
KNSA returned +125.82% over the past 12 months, compared with -17.69% for CORT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CORT or KNSA?
CORT has the lower trailing P/E at 47.8, versus 71.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Corcept Therapeutics and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.